Precision medicine for high-risk neuroblastoma [ 2018 - ]

Research Grant

Researchers: Dr David Croucher (Principal investigator) ,  A/Pr Alexander Swarbrick ,  Dr Jamie Fletcher ,  Prof Walter Kolch

Brief description Despite aggressive treatment, the survival rate for high-risk neuroblastoma patients is below 50%. We recently found that these poor-outcome neuroblastomas have a defect in a key drug response pathway, called the JNK pathway. Standard-of-care neuroblastoma drugs all require the JNK pathway to kill neuroblastoma cells, although we have now identified alternative drugs that do not require JNK. We now plan to demonstrate the efficacy of these drugs in neuroblastomas with a defective JNK pathway.

Funding Amount $660,005.00

Funding Scheme Project Grants

Notes Standard Project Grant